Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Brown R, Yang S, Weatherburn C, Gibson J, Ho PJ, Suen H, Hart D, Joshua D.

Leukemia. 2015 Feb;29(2):483-90. doi: 10.1038/leu.2014.204. Epub 2014 Jul 3.

PMID:
24990616
2.

Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C.

Blood. 2011 Apr 14;117(15):e120-30. doi: 10.1182/blood-2010-10-316026. Epub 2011 Jan 13.

3.

Analysis of hematopathology and alteration of JAK1/STAT3/STAT5 signaling axis in experimental myelodysplastic syndrome.

Daw S, Chatterjee R, Law A, Law S.

Chem Biol Interact. 2016 Dec 25;260:176-185. doi: 10.1016/j.cbi.2016.10.010. Epub 2016 Oct 8.

PMID:
27725143
4.

Different associations of CD45 isoforms with STAT3, PKC and ERK regulate IL-6-induced proliferation in myeloma.

Zheng X, Li AS, Zheng H, Zhao D, Guan D, Zou H.

PLoS One. 2015 Mar 17;10(3):e0119780. doi: 10.1371/journal.pone.0119780. eCollection 2015.

5.

Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.

Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J, McKay CJ.

J Gastrointest Surg. 2013 May;17(5):887-98. doi: 10.1007/s11605-013-2168-7. Epub 2013 Feb 23.

PMID:
23435739
6.
7.

An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.

Lin H, Kolosenko I, Björklund AC, Protsyuk D, Österborg A, Grandér D, Tamm KP.

Exp Cell Res. 2013 Mar 10;319(5):600-11. doi: 10.1016/j.yexcr.2012.12.006. Epub 2012 Dec 13.

PMID:
23246572
8.

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C.

Clin Colorectal Cancer. 2013 Mar;12(1):28-36. doi: 10.1016/j.clcc.2012.09.002. Epub 2012 Oct 17.

PMID:
23083634
9.

The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.

Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA, Kumar SK.

Leuk Res. 2016 May;44:32-9. doi: 10.1016/j.leukres.2016.03.003. Epub 2016 Mar 10.

PMID:
26994849
10.

High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.

Woost PG, Solchaga LA, Meyerson HJ, Shankey TV, Goolsby CL, Jacobberger JW.

Blood. 2011 Apr 14;117(15):e131-41. doi: 10.1182/blood-2010-10-316224. Epub 2011 Feb 17.

11.

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma.

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A.

BMC Cancer. 2012 Oct 16;12:478. doi: 10.1186/1471-2407-12-478.

12.

Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.

Ok CY, Chen J, Xu-Monette ZY, Tzankov A, Manyam GC, Li L, Visco C, Montes-Moreno S, Dybkær K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Zhao X, Ponzoni M, Ferreri AJ, Bertoni F, Farnen JP, Møller MB, Piris MA, Winter JN, Medeiros LJ, Young KH.

Clin Cancer Res. 2014 Oct 1;20(19):5113-23. doi: 10.1158/1078-0432.CCR-14-0683. Epub 2014 Aug 14.

13.

Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.

Haura EB, Zheng Z, Song L, Cantor A, Bepler G.

Clin Cancer Res. 2005 Dec 1;11(23):8288-94.

14.

The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.

Aleskandarany MA, Agarwal D, Negm OH, Ball G, Elmouna A, Ashankyty I, Nuglozeh E, Fazaludeen MF, Diez-Rodriguez M, Nolan CC, Tighe PJ, Green AR, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Feb;156(1):9-20. doi: 10.1007/s10549-016-3709-z. Epub 2016 Feb 23.

PMID:
26907764
15.

Signal tranducers and activators of transcription: expression and function in anti-neutrophil cytoplasmic antibody-associated vasculitis.

Wilde B, Hoerning A, Kribben A, Witzke O, Dolff S.

Mol Med Rep. 2014 Jun;9(6):2316-20. doi: 10.3892/mmr.2014.2062. Epub 2014 Mar 20.

PMID:
24676862
16.

Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.

Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ.

Clin Breast Cancer. 2016 Apr;16(2):113-22.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1.

17.

Patients with acute pancreatitis complicated by organ failure show highly aberrant monocyte signaling profiles assessed by phospho-specific flow cytometry.

Oiva J, Mustonen H, Kylänpää ML, Kyhälä L, Alanärä T, Aittomäki S, Siitonen S, Kemppainen E, Puolakkainen P, Repo H.

Crit Care Med. 2010 Aug;38(8):1702-8. doi: 10.1097/CCM.0b013e3181e7161c.

PMID:
20512034
18.

FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Redell MS, Ruiz MJ, Gerbing RB, Alonzo TA, Lange BJ, Tweardy DJ, Meshinchi S; Children's Oncology Group..

Blood. 2013 Feb 14;121(7):1083-93. doi: 10.1182/blood-2012-04-421925. Epub 2012 Dec 14.

19.

Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma.

Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC.

Blood. 2008 Oct 15;112(8):3403-11. doi: 10.1182/blood-2007-11-119362. Epub 2008 Jul 17.

20.

Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP.

Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, Micallef IN, Dogan A, Witzig TE.

Blood. 2012 Nov 22;120(22):4400-6. doi: 10.1182/blood-2012-05-428466. Epub 2012 Sep 27.

Supplemental Content

Support Center